Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zapaq Inc.

This article was originally published in Start Up

Executive Summary

The founders of Zapaq Inc. have a straightforward objective: to develop compounds that inhibit aspartic proteases. The goal is hardly surprising, given that one of the company's founders, Jordan Tang, PhD, of the Oklahoma Medical Research Foundation was the first scientist to determine the structure of an aspartic protease and explore its basic mechanisms.

You may also be interested in...



With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel